Daily Briefing · 2026-10-30

Lilly, Gilead, and Johnson & Johnson shares hit record highs even as tech stocks declined, delivering outsized gains to biopharma investors amid the broader tech selloff. Anthropic may face higher debt financing costs following its IPO after receiving a high junk credit rating rather than investment-grade status, limiting its access to cheaper capital. Mammoth Energy Services reported third quarter revenue up twelve percent year-over-year to one hundred thirty-two point three million dollars on strong pipeline services and compression equipment demand, though gross margins fell three percent on inflationary cost pressures. FTI Consulting reported third quarter revenue growth of eight percent year-over-year to seven hundred sixty-one million dollars, with adjusted EBITDA margin expanding to nineteen point two percent amid a competitive consulting environment. LyondellBasell reported a significant third quarter downturn, with declining revenues and profitability pressures weighing on shareholder returns. Sensient Technologies reported third quarter revenue growth of five percent to three hundred ninety-five million dollars, with adjusted operating margins expanding eighty basis points despite inflationary pressures. Standard Motor Products reported third quarter revenue down two percent year-over-year while gross margins compressed ninety basis points on unfavorable product mix and higher input costs. COPT Defense Properties reported third quarter results showing revenue increases across its defense-focused real estate portfolio, with rising occupancy and rental rate growth. Blockchain intelligence firms linked North Korea-affiliated hackers to a six point three billion dollar theft from Binance, with analysts calling the coming days a key test for Bitcoin and IBIT. Reddit shares fell roughly twenty-five percent in their largest-ever one-day drop after the company issued a disappointing revenue forecast, with analysts warning further declines may follow. AstraZeneca reported third quarter revenue growth of seventeen percent year-over-year, driven by strong oncology and specialty care performance and expanding operating margins.